Financial Contrast: MeiraGTx (NASDAQ:MGTX) & aTyr Pharma (NASDAQ:ATYR)Defense World · Sep 30, 2026
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of DirectorsGlobeNewsWire · Sep 23, 2026
Head-To-Head Analysis: Ascendis Pharma A/S (NASDAQ:ASND) versus MeiraGTx (NASDAQ:MGTX)Defense World · Sep 11, 2026
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing TideGuruFocus · Aug 26, 2026
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide PharmaceuticalPRNewsWire · Aug 26, 2026
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass EstimatesZacks Investment Research · Aug 13, 2026MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.46 | $1.71 | Beat |
| May 14, 2026 | -$0.43 | -$0.57 | Miss |
| Mar 26, 2026 | -$0.60 | $0.19 | Beat |
| Nov 13, 2025 | -$0.50 | -$0.62 | Miss |
| Aug 14, 2025 | -$0.52 | -$0.48 | Beat |
| May 13, 2025 | -$0.38 | -$0.51 | Miss |